Biomea Fusion is trading at $0.91, up 8.50%, with no identified company-specific announcement explaining the October 16 move.
- The gain follows the sharp October 14 decline; biotech ETF XBI is down 2.06%, so sector strength does not explain the rise.
- Recent Phase 1 BMF-650 results reported weight reduction, but placebo results in the most dramatic cohort complicated interpretation. The results preceded the selloff and are not a confirmed catalyst for this rebound.